Showing results (81-90 of 96) with videos related to
Sort By:
Pageof 10
Pilot and Feasibility Studies|January 25, 2024
Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D pilot): results of a feasibility randomised trial, Andrew J Farmer, Julie Allen, et al.Journal of Translational Medicine|January 23, 2019
Climate, human behaviour or environment: individual-based modelling of Campylobacter seasonality and strategies to reduce disease burdenStephen P Rushton, Roy A Sanderson, Peter J Diggle, et al.Human Vaccines & Immunotherapeutics|November 13, 2012
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trialRosalind Rowland, Ansar A Pathan, Iman Satti, et al.Journal of Medicinal Chemistry|January 30, 2014
Euodenine A: a small-molecule agonist of human TLR4Juliette E Neve, Hasanthi P Wijesekera, Sandra Duffy, et al.JMIR Research Protocols|February 21, 2022
Supporting People With Type 2 Diabetes in the Effective Use of Their Medicine Through Mobile Health Technology Integrated With Clinical Care to Reduce Cardiovascular Risk: Protocol for an Effectiveness and Cost-effectiveness Randomized Controlled TrialAndrew Farmer, Louise Jones, Nikki Newhouse, et al.Scientific Reports|April 30, 2017
Genome-wide fitness analyses of the foodborne pathogen Campylobacter jejuni in in vitro and in vivo modelsStefan P de Vries, Srishti Gupta, Abiyad Baig, et al.The Lancet. Infectious Diseases|April 15, 2024
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trialIman Satti, Julia L Marshall, Stephanie A Harris, et al.BMJ Open|November 22, 2011
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsAngela M Minassian, Rosalind Rowland, Natalie E R Beveridge, et al.Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.American Heart Journal|September 17, 2020
Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trialAndrew J Morrow, Thomas J Ford, Kenneth Mangion, et al.Pageof 10